Navigation Links
At opening of XVIII International AIDS Conference, scientific, community and political leaders applaud recent progress toward universal access and urge continued momentum to 'finish what we've started'
Date:7/19/2010

important human rights implications. The recent backtracking by donors on funding commitments to universal access and the failure of many low-income countries to demonstrate commitment to domestic financing of HIV treatment, highlight the volatility of health responses driven by political and financial expediency rather than respect for the right to health. The ongoing failure to mount a rights-based scale-up will not only violate the right to health and life of millions, but will destabilize health and socio-economic systems, requiring a belated response at a much greater cost.

Strategies for a Cure

Dr. Sharon Lewin (Australia) of the Alfred Hospital, Monash University and Burnet Institute outlined the multiple barriers to curing HIV, and examined potential avenues for achieving either a functional cure (long-term control of HIV in the absence of combination antiretroviral therapy) or a sterilizing cure (elimination of all HIV-infected cells). The major challenges include residual viral replication in patients receiving combination antiretroviral therapy (cART) and HIV's ability to sequester itself in anatomical reservoirs. The most significant barrier, however, is the establishment of a latent or "silent" infection in resting CD4+ T-cells. According to Lewin, recent advances in understanding which cells are latently infected and how latency is established and maintained may one day lead to interventions that could potentially reverse latent infection.

Studies of patients who can naturally control HIV have demonstrated that a functional cure may be possible with the most consistent finding among these patients being a potent immune response to HIV. One potential approach to achieving a sterilizing cure includes the very early initiation of cART in combination with agents that can reverse latent infection. Drugs such as histone deacetylase inhibitors, currently used and licensed for the treatment of some cancers, and cytokines
'/>"/>

Contact: Regina Aragon
Regina.Aragon@gmail.com
43-699-172-85713
International AIDS Society
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Less than one month to opening of world’s largest global congress on osteoporosis
2. Opening a new window on daylight
3. Tobacco plant thwarts caterpillar onslaught by opening flowers in the morning
4. Opening the gate to the cells recycling center
5. BIO-key(R) International To Exhibit at Oracle OpenWorld
6. Sentara begins international trial -- open at only 24 US locations
7. Perinatal Days and International Stillbirth Conference -- Nov.5-7
8. AVS 55th International Symposium & Exhibition, Oct. 19-24
9. Minnesota ecology professor wins international award for biodiversity and biofuels research
10. International Council for Science launches major research program on natural disasters
11. Innovations in Pediatric Medicine International Conference brings together pediatrics experts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... epigenetic processes to regulate its genes, and adapt to ... of the genome regulation taking place in the truffle, ... Biology and illustrates how the truffle deals with ... authors say this may shed light on how traits ... (Tuber melanosporum), also known as Prigord truffles, have a ...
(Date:7/30/2014)... Queen in Lewis Carroll,s Through the Looking Glass, ... University of Singapore improved a 35-year-old ecology model ... to millions of years. , The new model, ... the "Red Queen Effect," an evolutionary hypothesis introduced ... suggests that organisms must constantly increase their fitness ...
(Date:7/30/2014)... and tended her eggs until they hatched 4.5 years ... in the open-access journal PLOS ONE by ... colleagues. , Octopuses typically have a single reproductive period ... care of their fertilized eggs until they hatch. Shallow-water ... 3 months, but little is known about the brooding ...
Breaking Biology News(10 mins):How black truffles deal with the jumpers in their genome 2Classic Lewis Carroll character inspires new ecological model 2Classic Lewis Carroll character inspires new ecological model 3Deep-sea octopus has longest-known egg-brooding period 2
... / b3c newswire / - Kinaxo Biotechnologies GmbH has ... identify the protein kinase mTOR as a new ... a non-steroidal, anti-inflammatory Cox-2 inhibitor approved for the ... In addition, celecoxib’s anti-proliferative effect has earned it ...
... of memories for a lifetime. But when our eyes ... also creates temporary memories that help us process complex ... For decades, scientists have held that such short-term memories ... the course of several seconds. Now researchers at ...
... of healthy people can cause serious infections in premature ... university Karolinska Institutet have now found an explanation for ... to the skin and quickly develop dynamic ecosystems: the ... establishes itself on the child,s skin and mucous ...
Cached Biology News:KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex 2Some short-term memories die suddenly, no fading 2Tufted bacteria cause infection in premature babies 2
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... , July 30, 2014  Regeneron Pharmaceuticals, Inc. ... today announced that the Companies intend to use a ... priority review voucher in connection with the Biologics License ... entitles the holder to designate a BLA for priority ... the filing date instead of the standard 10-month review. ...
(Date:7/30/2014)... 2014 W. R. Grace & ... the REVELERIS® Prep purification system , a ... and other researchers to perform both flash and ... , With the REVELERIS® Prep purification system, researchers ... modes with a simple touch of the screen, ...
(Date:7/30/2014)... 2014  Decision Resources Group finds that the ... the United States believe ... will be the level of savings achievable by ... lower cost to patients. Payers plan to leverage ... pricing expectations in order to encourage physician prescribing ...
Breaking Biology Technology:Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Grace Launches New REVELERIS® Prep Purification System 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3
... KALAMAZOO, Mich., Oct. 28 Stryker Corporation (NYSE: SYK ... District of Massachusetts has returned an indictment charging Stryker Biotech ... with wire fraud, conspiracy to defraud the U.S. Food and ... statements to the FDA. The Company disclosed in March of ...
... INCLINE VILLAGE, Nev., Oct. 28 PDL BioPharma, Inc. ... has priced a $300 million securitization transaction intended to ... , Upon closing of the transaction, which is expected ... sell to QHP Royalty Sub LLC ("QHP"), a newly-formed ...
... , GAITHERSBURG, Md., Oct. 28 GenVec, Inc. (Nasdaq: ... the third quarter ended September 30, 2009 on Thursday, November ... call at 10:00 a.m. EST on Friday, November 6, 2009 ... http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) , To listen to ...
Cached Biology Technology:Stryker Statement in Response to the Indictment of Its Biotech Division 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3GenVec Announces Third Quarter 2009 Results Conference Call 2
... The Corning CellBIND surface is produced ... a more hydrophilic surface giving more consistent, ... yields. CellBIND enhances cell attachment and growth ... serum-free medium. • CellBIND may provide a ...
... Bio-Plex suspension array system, 100-240 V, uses ... up to 100 proteins and peptides in ... composed of up to 100 color-coded bead ... with a unique reactant (enzyme substrates, receptors, ...
...
... the revolutionary Luminex 100 System delivers a ... real time enhancing your operational efficiency. This ... Luminex 100, the XY Platform, and the ... you to simultaneously assay up to 100 ...
Biology Products: